ReforGene Raises nearly ¥100M Series A Financing

ReforGene, a leading biotechnology company focused on innovation and development of CRISPR-Cas technology,  announced the completion of a nearly RMB 100million Series A round financing. The Series A funding was led by Alwin Capital. Existing investor Legend Star also participated in the round.     

This round of financing will be used to continue to advance the progress of the research and development of existing innovative therapies, accelerate technology transformation and the construction of a talent system.

ReforGene is a high-tech company in the pre-clinical stage, dedicated to the development of therapeutically valuable genetic drugs. The R&D team comes from famous research institutions such as MD Anderson Cancer Center, New York University and Sun Yat-sen University. 

ReforGene starts from mastering the basic code of the essence of life activities, is driven by talents and technology, combines leading methods such as gene editing and genomics, and focuses on the innovation of a new generation of nucleic acid-level highly programmable drugs (programmable medicine). In the long term, Reforgene is committed to researching a variety of major diseases, including genetic diseases, chronic diseases and cancer, to serve patients.

CRISPR-Cas technology is an ideal gene therapy method, not only suitable for single-gene genetic diseases, such as thalassemia, hemophilia, IRD, etc., but also for cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases And malignant tumors and other major diseases.

ReforGene has the ability to innovate and develop gene editing components and the entire technical system, and is continuing to invest in gene editing drug research and development, including improving the efficiency of editing technology and reducing off-target risks. Guided by the ultimate clinical therapeutic value, establish clinical effects and safety, and develop highly competitive genetic drugs for patients in urgent need of treatment.

Alwin Capital is a leading venture capital in China specializing in early stage life science investments.